Underwriter Warns Of Biotech Risks

NU Online News Service, May 29, 12:57 p.m.EST?Improper and inadequate procedures governingbiotechnology companies' drug testing are exposing many of them tolawsuits, a New Jersey underwriter is warning.

"Inadequate informed consent forms, improper recruitment of testsubjects, and potential conflicts of interest between clinicalinvestigators and business partners leave many U.S. and Canadianbiotechnology companies exposed to clinical trials litigation,"according to Frank Goudsmit, a life sciences underwriting managerat Chubb & Son in Warren, N.J.

Continue Reading for Free

Register and gain access to:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.